已收盘 12-26 16:00:00 美东时间
-0.060
-0.46%
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
12-18 10:54
Morgan Stanley analyst Toni Kaplan maintains BrightView Hldgs (NYSE:BV) with a Equal-Weight and raises the price target from $12 to $13.
12-17 22:11
BTIG launched coverage of ten homebuilding and real estate services companies with a relatively cautious outlook. "YTD homebuilder earnings clearly display a challenging supply/demand dynamic, with pr...
12-02 21:53
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从6美元升至8美元;HC Wainwright & Co.:维持MediWound"买入"评级,目标价从31美元升至36美元
11-24 11:23
今日重点评级关注:Ascendiant Capital:维持Aclarion"买入"评级,目标价从22美元升至23美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从24美元升至26美元
11-21 15:50
Baird analyst Andrew Wittmann maintains BrightView Hldgs (NYSE:BV) with a Outperform and lowers the price target from $19 to $15.
11-20 22:09
BrightView Holdings, Inc. (NYSE: BV) (the "Company" or "BrightView"), the leading commercial landscaping services company in the United States, today reported unaudited results for the three months and full fiscal year
11-20 05:12
BrightView Holdings shares are trading lower after the company reported worse-t...
11-20 05:12
BrightView Hldgs (NYSE:BV) sees FY2026 sales of $2.670 billion-$2.730 billion vs $2.690 billion analyst estimate.
11-20 05:12
BrightView Hldgs (NYSE:BV) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.32 by 14.83 percent. This is a 10 percent decrease over earnings of $0.30 per share from the
11-20 05:11